This article is more than 5 years old. Information may no longer be current.
Patient, tumor characteristics predicted surgical outcomes in primary cutaneous mucinous carcinoma
Click Here to Manage Email Alerts
Patients with primary cutaneous mucinous carcinoma who were older and Asian had improved postsurgical outcomes, but tumors that were large, persistent and located on the trunk were associated with poorer outcomes, according to study results.
Researchers used the MEDLINE, Embase, and Cumulative Index to Nursing and Allied Health databases from 1952 to 2010 to identify 159 patients with primary cutaneous mucinous carcinoma. The mean age of patients was 63.5 years. Most were non-Hispanic white (77.2%) and male (54.7%).
Most patients underwent traditional surgical excision (85.5%), and 9.4% underwent Mohs’ micrographic surgery. Recurrent disease or metastasis occurred in 34% of patients who underwent excision.
Mean follow-up was 30.1 months for patients who underwent excision and 23.1 months for those who underwent Mohs’ surgery.
Researchers found patients with tumors on the trunk experienced poorer outcomes after surgery (OR=103.24; P=.005) than patients with tumors on the head or neck.
Longer follow-up also was predictive of poor outcomes (OR=1.07; P=.01).
Tumors that were larger (OR=6.71; P=.14) and persistent for longer prior to surgery (OR=1.02; P=.11) were also linked to poorer outcomes, yet these associations were not statistically significant.
Outcomes were more favorable among patients who were older compared with those who were younger (OR=0.93; P=.04), and among Asian patients compared with non-Hispanic whites (OR=0.02; P=.01).
“In that the source data for this study were case-level reports and not randomized controlled trials, inferences about cure rates must be viewed in the context of the limitations of the data and the many likely biases,” the researchers wrote. “However, given the rarity of primary cutaneous mucinous carcinoma, it would be difficult to get a sufficient number of cases with a prospective study, and we believe that our analysis does provide new insight into this rare tumor, helping to further characterize factors that may influence recurrence and metastasis rates.”
Disclosure: The researchers report consultant roles with and research funding/royalties from Allergan, Amway, BioForm Medical, Elsevier, Leo Pharma, Medicis and Ulthera.
Click Here to Manage Email Alerts